Use of etidronate (ehdp) in paget's disease of bone
β Scribed by C. Conrad Johnston Jr; M. R. A. Khairi; P. J. Meunier
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- English
- Weight
- 382 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Etidronate used in recommended doses (usually 5 mg/kg/day for 6 months) produces symptomatic improvement in approximately 60% of patients. The serum alkaline phosphatase and urinary hydroxyproline are reduced to about 50% of initial values. A sustained remission occurs in many patients and retreatment is usually effective upon relapse. The abnormally elevated osteoclast count and resorption surfaces are reduced, and at the low dose there is no accumulation of osteoid. The medication is generally well tolerated and at the recommended dosage there is no evidence of increased fracture rate.
π SIMILAR VOLUMES
Paget disease of the bone is a common skeletal disorder. Recently, a gene for Paget disease was localized to 18q with subsequent evidence for linkage heterogeneity. We report the identification and clinical characterization of a large pedigree of Paget disease and demonstrate that the Paget disease
## Abstract The combination of autosomal dominant, early onset Paget disease of bone (PDB) and muscular dystrophy is an unusual disorder. We recently mapped the disorder in a large family from central Illinois with PDB and proximal limbβgirdle type of muscular dystrophy (LGMD), and in 3 additional